Literature DB >> 27173171

The Highly Evolvable Antibody Fc Domain.

Hye In Park1, Hyun Woung Yoon1, Sang Taek Jung2.   

Abstract

The Fc region of the IgG antibody recruits immune leukocytes or serum complement molecules, which in turn triggers the clearance of defective cells such as tumor cells or infected cells. In addition, the Fc region is crucial for the prolonged serum persistence of circulating IgG antibodies through an intracellular trafficking and recycling mechanism. Recently, the utility of antibody Fc has been further expanded to include a new class of antigen-binding scaffolds. This review presents the recent progress in the field of antibody Fc engineering and highlights new biomolecular, cellular, and evolutionary approaches to overcome the limitations of conventional monoclonal therapeutic antibodies by engineering the antibody Fc domain.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibody Fc; antibody engineering; effector functions; serum half-life

Mesh:

Substances:

Year:  2016        PMID: 27173171     DOI: 10.1016/j.tibtech.2016.04.005

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  13 in total

1.  Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.

Authors:  Migyeong Jo; Hyeong Sun Kwon; Kwang-Hoon Lee; Ji Chul Lee; Sang Taek Jung
Journal:  MAbs       Date:  2017-12-07       Impact factor: 5.857

2.  CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance.

Authors:  Yi-Lin Chen; Ashley L Marcinkiewicz; Tristan A Nowak; Rakhi Tyagi Kundu; Zhuyun Liu; Ulrich Strych; Maria Elena Bottazzi; Wen-Hsiang Chen; Yi-Pin Lin
Journal:  Infect Immun       Date:  2022-07-05       Impact factor: 3.609

Review 3.  Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life.

Authors:  Abhishek Saxena; Donghui Wu
Journal:  Front Immunol       Date:  2016-12-12       Impact factor: 7.561

4.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity.

Authors:  James S Foster; Angela D Williams; Sallie Macy; Tina Richey; Alan Stuckey; Daniel Craig Wooliver; Richa Koul-Tiwari; Emily B Martin; Stephen J Kennel; Jonathan S Wall
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 5.  Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.

Authors:  Hongyan Liu; Abhishek Saxena; Sachdev S Sidhu; Donghui Wu
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

6.  Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Authors:  Kristina M Ilieva; Judit Fazekas-Singer; Daniela Y Achkova; Tihomir S Dodev; Silvia Mele; Silvia Crescioli; Heather J Bax; Anthony Cheung; Panagiotis Karagiannis; Isabel Correa; Mariangela Figini; Rebecca Marlow; Debra H Josephs; Andrew J Beavil; John Maher; James F Spicer; Erika Jensen-Jarolim; Andrew N Tutt; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2017-09-11       Impact factor: 7.561

7.  Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations.

Authors:  Amram Torgeman; Eyal Ozeri; Alon Ben David; Eran Diamant; Osnat Rosen; Arieh Schwartz; Ada Barnea; Arik Makovitzki; Avishai Mimran; Ran Zichel
Journal:  Toxins (Basel)       Date:  2017-05-29       Impact factor: 4.546

8.  Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.

Authors:  Aran F Labrijn; Joyce I Meesters; Matthew Bunce; Anthony A Armstrong; Sandeep Somani; Tom C Nesspor; Mark L Chiu; Işil Altintaş; Sandra Verploegen; Janine Schuurman; Paul W H I Parren
Journal:  Sci Rep       Date:  2017-05-30       Impact factor: 4.379

9.  The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.

Authors:  Shiri Davidi; Ella Fremder; Tal Kan; Ziv Raviv; Michael Timaner; Nathan Karin; Dov Hershkovitz; Ami Arohneim; Yuval Shaked
Journal:  Oncotarget       Date:  2017-03-07

10.  DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.

Authors:  Claudio Sustmann; Steffen Dickopf; Jörg T Regula; Hubert Kettenberger; Michael Mølhøj; Christian Gassner; Diana Weininger; Sebastian Fenn; Tobias Manigold; Lothar Kling; Klaus-Peter Künkele; Manfred Schwaiger; Birgit Bossenmaier; Julia J Griese; Karl-Peter Hopfner; Alexandra Graff-Meyer; Henning Stahlberg; Philippe Ringler; Matthias E Lauer; Ulrich Brinkmann; Wolfgang Schaefer; Christian Klein
Journal:  MAbs       Date:  2019-09-17       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.